Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam: PHARM) (Nasdaq:PHAR) revealed on Monday that it will distribute RUCONEST (conestat alfa) in the Middle East and North Africa (MENA) under an exclusive license agreement with NewBridge Pharmaceuticals, headquartered in Dubai, UAE.

The terms of the agreement provide NewBridge with access to Pharming's RUCONEST for the treatment of acute hereditary angioedema (HAE) in MENA. HAE is a rare genetic condition characterized by recurrent, unpredictable episodic swellings of mucosal or cutaneous sites.

In conjunction with the agreement, NewBridge will be responsible for the named patient supply and, where applicable, marketing of RUCONEST in the MENA region.

According to the company, RUCONEST is a plasma-free recombinant human C1 esterase inhibitor (rhC1INH) protein replacement therapy approved for the treatment of acute attacks of HAE in adults and children aged two years and over. RUCONEST is reportedly approved by the US FDA and EMA and commercialised in over 20 countries.